Cel-Sci Corporation (NYSEAMERICAN:CVM) Sees Significant Increase in Short Interest

Cel-Sci Corporation (NYSEAMERICAN:CVM) was the recipient of a large growth in short interest during the month of January. As of January 30th, there was short interest totaling 522,417 shares, a growth of 28.5% from the January 15th total of 406,465 shares. Based on an average daily trading volume, of 102,730 shares, the short-interest ratio is currently 5.1 days. Approximately 7.2% of the company’s shares are sold short. Approximately 7.2% of the company’s shares are sold short. Based on an average daily trading volume, of 102,730 shares, the short-interest ratio is currently 5.1 days.

Hedge Funds Weigh In On Cel-Sci

Several hedge funds and other institutional investors have recently bought and sold shares of CVM. HighTower Advisors LLC acquired a new stake in Cel-Sci during the 4th quarter worth about $53,000. HRT Financial LP bought a new stake in shares of Cel-Sci during the 4th quarter valued at about $60,000. US Bancorp DE acquired a new stake in Cel-Sci during the third quarter worth approximately $80,000. Renaissance Technologies LLC bought a new stake in Cel-Sci in the fourth quarter worth approximately $81,000. Finally, Jane Street Group LLC acquired a new position in Cel-Sci in the fourth quarter valued at approximately $83,000. Institutional investors and hedge funds own 12.08% of the company’s stock.

Cel-Sci Trading Up 6.5%

Shares of Cel-Sci stock traded up $0.30 during midday trading on Monday, reaching $4.90. The company had a trading volume of 37,751 shares, compared to its average volume of 72,484. The firm has a market cap of $41.21 million, a PE ratio of -0.50 and a beta of 0.77. The stock has a fifty day moving average price of $5.46 and a 200 day moving average price of $7.54. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.26 and a quick ratio of 2.20. Cel-Sci has a fifty-two week low of $1.98 and a fifty-two week high of $20.41.

About Cel-Sci

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.